Výsledky vyhledávání - "Shoshana Distenfeld"

Moderate dose serial therapy for aged and resistant patients with cholangiocarcinomas

Autor: AJ Book, Daniel Gurell, Azriel Hirschfeld, Howard W. Bruckner, Myron Schwartz, Robert De Jager, Van T. Nghiem, Fred Bassali, Shoshana Distenfeld

Publikováno v: Journal of Clinical Oncology. 39:e16160-e16160

e16160 Background: Advanced (Adv) intrahepatic IH Cholangiocarcinoma BD trials found multi-drug, sequences (GFLIO) safely expand eligibility (El) for patients (pts) of all ages -/+ resistant Ca (R). Two series had response/survival (S) of 80% / > 2 y

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::525695372a42efff9fdf88b814c49f63
https://doi.org/10.1200/jco.2021.39.15_suppl.e16160

Zobrazit plný text záznamu

Blood tests to predict one- to two-year survival of patients with difficult cancers

Autor: AJ Book, Howard W. Bruckner, Shoshana Distenfeld, Fred Bassali, Robert De Jager, Azriel Hirschfeld, Elisheva Dusowitz

Publikováno v: Journal of Clinical Oncology. 39:e16158-e16158

e16158 Background: A sequence of drug combinations produces > 1 median (M) -strong 2-year (yr) survival (S) (Bruckner et al AACR 14 Antica Res (ACR) 16, 18 SIGO 19). Trials included high-risk patients (pts). Each initial series has 5-yr Ss, after pts

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da530cb3bec892b5a55deb9cc51d3472
https://doi.org/10.1200/jco.2021.39.15_suppl.e16158

Zobrazit plný text záznamu

Survival and prognostic tests in a real-world phase II experience with a safe, moderate-dose, sequential chemotherapy (CT) algorithm (ALGO) for metastatic pancreatic adenocarcinoma (PANC)

Autor: Howard W. Bruckner, Robert De Jager, Shoshana Distenfeld, Fred Bassali, Azriel Hirschfeld, Van T. Nghiem, AJ Book, Noah Weinberger, Daniel Gurell

Publikováno v: Journal of Clinical Oncology. 38:e16763-e16763

e16763 Background: Gemcitabine (G), 5-fluorouracil (F), leucovorin (L), irinotecan (I), and oxaliplatin (O), (GFLIO) is safe, employs moderate 1/2-1/3 dosages, offers expanded eligibility (0-2 ECOG PS; no age limit)). Each step reverse resistance (RR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b347d8f4b31d3b99db2712bb533d921
https://doi.org/10.1200/jco.2020.38.15_suppl.e16763

Zobrazit plný text záznamu

MODERATE SEQUENTIAL THIRD- TO FOURTH-LINE CHEMOTHERAPY (CT) ALGORITHMS (ALGO) FOR THE ELDERLY WITH RESISTANT COLORECTAL CANCER (R-CRC)

Autor: Van T. Nghiem, Howard W. Bruckner, Azriel Hirschfeld, R. De Jager, N. Weinberger, Shoshana Distenfeld, Daniel Gurell, AJ Book

Publikováno v: Journal of Geriatric Oncology. 10:S47-S48

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9bd81ce1b519efe01b7c9b2d5bb14684
https://doi.org/10.1016/s1879-4068(19)31196-8

Zobrazit plný text záznamu

MODERATE DOSE SEQUENTIAL CHEMOTHERAPY (CT) ALGORITHMS (ALGOS) FOR THE ELDERLY WITH AND WITHOUT RESISTANT CANCERS (R-C)

Autor: Fred Bassali, Shoshana Distenfeld, Howard W. Bruckner, Daniel Gurell, R. De Jager, Azriel Hirschfeld, N. Weinberger, Van T. Nghiem, AJ Book

Publikováno v: Journal of Geriatric Oncology. 10:S39

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5eb219226f13e61ca1cf78ad47b308a
https://doi.org/10.1016/s1879-4068(19)31181-6

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání